Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% ...
http://ift.tt/2wmLxWF
Παρασκευή 18 Αυγούστου 2017
Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου